Sunesis Pharmaceuticals - Inspired to Make a Difference in Cancer Patients Lives.

Partnering Opportunities


Vecabrutinib

As we complete the Phase 1b dose-escalation portion of our ongoing clinical trial, we are open to meeting with companies who are interested in commercializing vecabrutinib in certain regions outside the U.S. We are also open to considering a co-development partnership after establishing clinical proof of concept, which would allow for more aggressive development while providing for Sunesis to retain significant upside.
If you are interested in finding out more about potential partnering opportunities for vecabrutinib, please email us at [email protected] .

SNS-510

Inhibition of PDK1 has yielded promising non-clinical results in a variety of tumor types. As we continue to characterize the compound and realize the breadth of this opportunity, we believe that SNS-510 may be a candidate for an earlier co-development partnership with a larger pharmaceutical company with significant resources.
If you are interested in finding out more about potential partnering opportunities for SNS-510, please email us at [email protected]